Intensification of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: patient selection and overview of doublet and triplet therapy data.
作者信息
Shevach Jeffrey W, Park Joseph J, Armstrong Andrew J
机构信息
Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC USA.
Department of Medicine, Duke University, Durham NC USA.
出版信息
Adv Oncol. 2024 May;4(1):185-198. doi: 10.1016/j.yao.2023.12.006. Epub 2024 Feb 3.
Abstract
摘要
相似文献
1
Intensification of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: patient selection and overview of doublet and triplet therapy data.转移性激素敏感性前列腺癌中雄激素剥夺治疗的强化：患者选择及双联和三联疗法数据概述
Adv Oncol. 2024 May;4(1):185-198. doi: 10.1016/j.yao.2023.12.006. Epub 2024 Feb 3.
2
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.三药联合或两药联合治疗转移性激素敏感型前列腺癌患者：系统评价和网络荟萃分析。
Eur Urol Focus. 2023 Jan;9(1):96-105. doi: 10.1016/j.euf.2022.08.007. Epub 2022 Sep 1.
3
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
4
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.雄激素受体信号抑制剂联合多西他赛与雄激素剥夺疗法治疗转移性激素敏感前列腺癌：系统评价和荟萃分析。
Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19.
5
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?转移性激素敏感型前列腺癌强化全身治疗的成本效益：三联疗法是否具有成本效益？
Eur Urol Oncol. 2024 Aug;7(4):870-876. doi: 10.1016/j.euo.2023.11.013. Epub 2023 Dec 6.
6
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.局部晚期和转移性激素敏感性前列腺癌的联合治疗
Eur Urol. 2025 Apr;87(4):455-467. doi: 10.1016/j.eururo.2025.01.010. Epub 2025 Feb 12.
7
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.三药联合或两药联合治疗转移性激素敏感型前列腺癌：按疾病负荷分层的更新网络荟萃分析。
Eur Urol Focus. 2023 Sep;9(5):838-842. doi: 10.1016/j.euf.2023.03.024. Epub 2023 Apr 11.
8
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data.转移性激素敏感性前列腺癌患者的三联或双联疗法：一项纳入ARANOTE数据的更新网络荟萃分析
Eur Urol Focus. 2024 Dec 5. doi: 10.1016/j.euf.2024.11.004.
9
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.转移性激素敏感型前列腺癌与联合治疗结局：综述。
JAMA Oncol. 2024 Jun 1;10(6):807-820. doi: 10.1001/jamaoncol.2024.0591.
10
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].雄激素剥夺疗法联合化疗±雄激素受体靶向药物治疗转移性激素敏感性前列腺癌
Urologie. 2023 Apr;62(4):360-368. doi: 10.1007/s00120-023-02029-0. Epub 2023 Feb 10.
本文引用的文献
1
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
2
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙治疗转移性去势抵抗性前列腺癌（PROpel）：一项随机、双盲、3期试验的最终预设总生存结果
Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12.
3
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.阿帕鲁胺联合雄激素剥夺疗法用于转移性去势敏感性前列腺癌患者的临床亚组：随机临床TITAN研究的亚组分析
Eur J Cancer. 2023 Nov;193:113290. doi: 10.1016/j.ejca.2023.113290. Epub 2023 Aug 11.
4
Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.根据内脏转移部位对转移性前列腺癌患者进行总生存分析
Clin Genitourin Cancer. 2024 Apr;22(2):47-55.e2. doi: 10.1016/j.clgc.2023.08.004. Epub 2023 Aug 11.
5
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.哪些转移性激素敏感性前列腺癌患者从多西他赛治疗中获益：来自随机试验的个体参与者数据的系统评价和荟萃分析。
Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9.
6
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.转移性激素敏感型前列腺癌治疗的临床试验研究能否转化为患者在“真实世界”中获得治疗的机会？一项系统评价。
Eur Urol Oncol. 2024 Feb;7(1):14-24. doi: 10.1016/j.euo.2023.05.002. Epub 2023 Jun 27.
7
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.泰拉唑帕尼联合恩扎卢胺治疗一线转移性去势抵抗性前列腺癌（TALAPRO-2）：一项随机、安慰剂对照、III 期临床试验。
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
8
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.恩扎卢胺联合雄激素剥夺疗法治疗寡转移性激素敏感性前列腺癌的疗效：ARCHES 的事后分析。
Eur Urol. 2023 Aug;84(2):229-241. doi: 10.1016/j.eururo.2023.04.002. Epub 2023 May 12.
9
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙联合泼尼松或联合恩扎卢胺治疗开始去势治疗的转移性前列腺癌患者：STAMPEDE 平台方案两项随机 3 期试验的最终结果。
Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.
10
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.寡转移前列腺癌间歇性激素治疗中加入转移灶定向治疗：EXTEND 期 2 随机临床试验。
JAMA Oncol. 2023 Jun 1;9(6):825-834. doi: 10.1001/jamaoncol.2023.0161.
Zotero 插件